Skip navigation
Skip to main content

Browsing by Author Gebski, Val

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:  
Showing results 1 to 7 of 7
PreviewIssue DateTitleAuthor(s)
5-Mar-2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerPrice, Timothy J; Bruhn, Maressa A; Lee, Chee K; Hardingham, Jennifer E; Townsend, Amanda R; Mann, Kristy P; Simes, John; Weickhardt, Andrew; Wrin, Joseph W; Wilson, Kate; Gebski, Val; van Hazel, Guy; Robinson, Bridget; Cunningham, David; Tebbutt, Niall C
25-Feb-2013The cost-effectiveness of total laparoscopic hysterectomy compared to total abdominal hysterectomy for the treatment of early stage endometrial cancerGraves, Nicholas; Janda, Monica; Merolini, Katherina; Gebski, Val; Obermair, Andreas
2018Data maturity and follow-up in time-to-event analysesGebski, Val; Garès, Valérie; Gibbs, Emma; Byth, Karen
Feb-2011Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) StudyDavis, Timothy ME; Ting, Ru-Dee; Best, James D; Donoghoe, Mark; Drury, Paul L; Sullivan, David R; Jenkins, Alicia J; O'Connell, Rachel L; Whiting, Malcolm; Glasziou, Paul; Simes, R John; Kesaniemi, Y Antero; Gebski, Val; Scott, Russell; Keech, Anthony C
27-Aug-2013Is home warfarin self-management effective? Results of the Randomised Self-Management of Anticoagulation Research TrialWarfarin SMART investigators; Dignan, Rebecca; Keech, Anthony; Gebski, Val; Mann, Kristy; Hughes, Clifford
15-Oct-2014Sentinel-lymph-node-based management or routine axillary clearance? Three-year outcomes of the RACS Sentinel Node Biopsy versus Axillary Clearance (SNAC) 1 trialWetzig, Neil; Gill, Peter Grantley; Zannino, Diana; Stockler, Martin R; Gebski, Val; Ung, Owen; Campbell, Ian; Simes, R John
10-Jun-2011Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysisClarke, Stephen; Yip, Sonia; Brown, Chris; Van Hazel, Guy; Ransom, David T; Goldstein, David; Jeffrey, G Mark; Tebbutt, Niall C; Buck, Martin; Lowenthal, Raymond M; Boland, Amy; Gebski, Val; Zalcberg, John; Simes, R John